马来西亚受试者2型糖尿病患者血清可溶性CD26/二肽基肽酶-IV水平及其与代谢综合征和抗糖尿病药物治疗的关系
Serum Levels of Soluble CD26/Dipeptidyl Peptidase-IV in Type 2 Diabetes Mellitus and Its Association with Metabolic Syndrome and Therapy with Antidiabetic Agents in Malaysian Subjects.
作者信息
Ahmed Radwan H, Huri Hasniza Zaman, Al-Hamodi Zaid, Salem Sameer D, Muniandy Sekaran
机构信息
Department of Molecular Medicine, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia.
Department of Pharmacy, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia; Clinical Investigation Centre, University Malaya Medical Centre, Kuala Lumpur, Malaysia.
出版信息
PLoS One. 2015 Oct 16;10(10):e0140618. doi: 10.1371/journal.pone.0140618. eCollection 2015.
BACKGROUND
A soluble form of CD26/dipeptidyl peptidase-IV (sCD26/DPP-IV) induces DPP-IV enzymatic activity that degrades incretin. We investigated fasting serum levels of sCD26/DPP-IV and active glucagon-like peptide-1 (GLP-1) in Malaysian patients with type 2 diabetes mellitus (T2DM) with and without metabolic syndrome (MetS), as well as the associations between sCD26/DPP-IV levels, MetS, and antidiabetic therapy.
METHODS
We assessed sCD26/DPP-IV levels, active GLP-1 levels, body mass index (BMI), glucose, insulin, A1c, glucose homeostasis indices, and lipid profiles in 549 Malaysian subjects (including 257 T2DM patients with MetS, 57 T2DM patients without MetS, 71 non-diabetics with MetS, and 164 control subjects without diabetes or metabolic syndrome).
RESULTS
Fasting serum levels of sCD26/DPP-IV were significantly higher in T2DM patients with and without MetS than in normal subjects. Likewise, sCD26/DPP-IV levels were significantly higher in patients with T2DM and MetS than in non-diabetic patients with MetS. However, active GLP-1 levels were significantly lower in T2DM patients both with and without MetS than in normal subjects. In T2DM subjects, sCD26/DPP-IV levels were associated with significantly higher A1c levels, but were significantly lower in patients using monotherapy with metformin. In addition, no significant differences in sCD26/DPP-IV levels were found between diabetic subjects with and without MetS. Furthermore, sCD26/DPP-IV levels were negatively correlated with active GLP-1 levels in T2DM patients both with and without MetS. In normal subjects, sCD26/DPP-IV levels were associated with increased BMI, cholesterol, and LDL-cholesterol (LDL-c) levels.
CONCLUSION
Serum sCD26/DPP-IV levels increased in T2DM subjects with and without MetS. Active GLP-1 levels decreased in T2DM patients both with and without MetS. In addition, sCD26/DPP-IV levels were associated with Alc levels and negatively correlated with active GLP-1 levels. Moreover, metformin monotherapy was associated with reduced sCD26/DPP-IV levels. In normal subjects, sCD26/DPP-IV levels were associated with increased BMI, cholesterol, and LDL-c.
背景
可溶性CD26/二肽基肽酶-IV（sCD26/DPP-IV）可诱导DPP-IV酶活性，该活性会降解肠促胰岛素。我们研究了马来西亚2型糖尿病（T2DM）患者（伴有和不伴有代谢综合征（MetS））空腹血清中sCD26/DPP-IV和活性胰高血糖素样肽-1（GLP-1）的水平，以及sCD26/DPP-IV水平、MetS和抗糖尿病治疗之间的关联。
方法
我们评估了549名马来西亚受试者（包括257名伴有MetS的T2DM患者、57名不伴有MetS的T2DM患者、71名伴有MetS的非糖尿病患者和164名无糖尿病或代谢综合征的对照受试者）的sCD26/DPP-IV水平、活性GLP-1水平、体重指数（BMI）、血糖、胰岛素、糖化血红蛋白（A1c）、葡萄糖稳态指数和血脂谱。
结果
伴有和不伴有MetS的T2DM患者空腹血清sCD26/DPP-IV水平均显著高于正常受试者。同样，伴有MetS的T2DM患者的sCD26/DPP-IV水平显著高于伴有MetS的非糖尿病患者。然而，伴有和不伴有MetS的T2DM患者的活性GLP-1水平均显著低于正常受试者。在T2DM受试者中，sCD26/DPP-IV水平与显著更高的A1c水平相关，但在使用二甲双胍单药治疗的患者中显著更低。此外，伴有和不伴有MetS的糖尿病受试者之间sCD26/DPP-IV水平无显著差异。此外，伴有和不伴有MetS的T2DM患者中，sCD26/DPP-IV水平与活性GLP-1水平呈负相关。在正常受试者中，sCD26/DPP-IV水平与BMI、胆固醇和低密度脂蛋白胆固醇（LDL-c）水平升高相关。
结论
伴有和不伴有MetS的T2DM受试者血清sCD26/DPP-IV水平均升高。伴有和不伴有MetS的T2DM患者活性GLP-1水平均降低。此外，sCD26/DPP-IV水平与A1c水平相关，与活性GLP-1水平呈负相关。此外，二甲双胍单药治疗与sCD26/DPP-IV水平降低相关。在正常受试者中，sCD26/DPP-IV水平与BMI、胆固醇和LDL-c升高相关。
Zotero 插件